Common new active substance approvals across major regulatory authorities (multi-year total) vs Autoimmune cell therapy and T-cell engager trial starts

Common new active substance approvals across major regulatory authorities (multi-year total) (multi-month) and Autoimmune cell therapy and T-cell engager trial starts (annual) worldwide. They are published at different intervals, so each is drawn on its own rather than matched period by period.

Change the pair

Compare different indicators

The series

Over time

Global. Common new active substance approvals across major regulatory authorities (multi-year total) is published as multi-month figures and autoimmune cell therapy and T-cell engager trial starts as annual ones, so they are drawn on separate charts, and no period is matched between them. Read each on its own.

Common new active substance approvals across major regulatory authorities (multi-year total)

Unit: count · 2 observations

Line chart
Common new active substance approvals across major regulatory authorities (multi-year total)Common new active substance approvals across major regulatory authorities (multi-year total). 2 observations from 2016–2020 to 2021–2025, ranging from 37 to 52. Latest value 52 (2021–2025). 0 10 20 30 40 50 60 2016 2017 2018 2019 2020 2021 37 52
Common new active substance approvals across major regulatory authorities (multi-year total)Common new active substance approvals across major regulatory authorities (multi-year total). 2 observations from 2016–2020 to 2021–2025, ranging from 37 to 52. Latest value 52 (2021–2025). 0 20 40 60 2016 2017 2018 2019 2020 2021 37 52
Common new active substance approvals across major regulatory authorities (multi-year total)Common new active substance approvals across major regulatory authorities (multi-year total). 2 observations from 2016–2020 to 2021–2025, ranging from 37 to 52. Latest value 52 (2021–2025). 0 20 40 60 2016 2017 2018 2019 2020 2021 37 52
View the underlying data
Common new active substance approvals across major regulatory authorities (multi-year total)
Period Type Value
2016–2020 Actual 37
2021–2025 Actual 52
Source: CIRS · CC BY 4.0 · Full series

Autoimmune cell therapy and T-cell engager trial starts

Unit: count · 6 observations

Line chart
Autoimmune cell therapy and T-cell engager trial startsAutoimmune cell therapy and T-cell engager trial starts. 6 observations from 2020 to 2025, ranging from 2 to 112. Latest value 112 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 2 112
Autoimmune cell therapy and T-cell engager trial startsAutoimmune cell therapy and T-cell engager trial starts. 6 observations from 2020 to 2025, ranging from 2 to 112. Latest value 112 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 2 112
Autoimmune cell therapy and T-cell engager trial startsAutoimmune cell therapy and T-cell engager trial starts. 6 observations from 2020 to 2025, ranging from 2 to 112. Latest value 112 (2025). 0 30 60 90 120 2020 2021 2022 2023 2024 2025 2 112
View the underlying data
Autoimmune cell therapy and T-cell engager trial starts
Period Type Value
2020 Actual 2
2021 Actual 7
2022 Actual 6
2023 Actual 17
2024 Actual 91
2025 Actual 112
Source: ClinicalTrials.gov · CC BY 4.0 · Full series

Shared periods

Side by side

No period lines up: common new active substance approvals across major regulatory authorities (multi-year total) is multi-month and autoimmune cell therapy and T-cell engager trial starts is annual. A month and a year are not the same measurement window, so no row pairs them.

Provenance

Where these numbers come from

Common new active substance approvals across major regulatory authorities (multi-year total)

Total count of new active substances approved across all designated major regulatory authorities during the period.

2 observations charted in Global · source organisations: CIRS

Autoimmune cell therapy and T-cell engager trial starts

Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related